Richard Pops (Photographer: Patrick T. Fallon/Bloomberg via Getty Images)

Alk­er­mes wins FDA nod for com­bo med with an­tipsy­chot­ic olan­za­p­ine — this time with­out the weight gain red flags

Alk­er­mes has had a rough go in the past few years, mak­ing the de­ci­sion to slice away a healthy por­tion of its R&D work­force last year af­ter a ma­jor set­back in de­pres­sion. The drug­mak­er placed a lot of hope in an­tipsy­chot­ic drug ALKS 3831 to turn things around, and af­ter a win­ning ad­comm late last year that bet is fi­nal­ly pay­ing off.

The FDA on Tues­day ap­proved Alk­er­mes’ Ly­balvi (olan­za­p­ine and sami­dor­phan) to treat schiz­o­phre­nia and bipo­lar 1 dis­or­der, the com­pa­ny said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.